- Home
- RIGL vs FFIC Comparison
RIGL vs FFIC Comparison
Compare RIGL & FFIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RIGL | FFIC |
|---|---|---|
| Founded | 1996 | 1929 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 564.7M | 510.6M |
| IPO Year | 2000 | 1996 |
Fundamental Metrics
Financial Performance| Metric | RIGL | FFIC |
|---|---|---|
| Price | $29.36 | $16.19 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 1 |
| Target Price | ★ $45.67 | $16.80 |
| AVG Volume (30 Days) | ★ 313.7K | 200.4K |
| Earning Date | 05-05-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 5.50% |
| EPS Growth | ★ 1867.68 | 151.43 |
| EPS | ★ 19.48 | 0.54 |
| Revenue | ★ $294,282,000.00 | $7,455,000.00 |
| Revenue This Year | N/A | $14.57 |
| Revenue Next Year | $12.75 | $6.64 |
| P/E Ratio | ★ $1.48 | $29.81 |
| Revenue Growth | ★ 64.15 | 7.31 |
| 52 Week Low | $16.88 | $11.13 |
| 52 Week High | $52.24 | $17.79 |
Technical Indicators
Market Signals| Indicator | RIGL | FFIC |
|---|---|---|
| Relative Strength Index (RSI) | 46.01 | 55.53 |
| Support Level | $28.08 | $16.12 |
| Resistance Level | $30.59 | $16.63 |
| Average True Range (ATR) | 1.13 | 0.37 |
| MACD | -0.22 | -0.00 |
| Stochastic Oscillator | 16.16 | 62.38 |
Price Performance
Historical ComparisonAbout RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.
About FFIC Flushing Financial Corporation
Flushing Financial Corp is a bank holding company. Through its subsidiary, the company is engaged in attracting retail deposits from the general public and investing those deposits together with funds generated from ongoing operations and borrowings, mainly in originations and purchases of multi-family residential properties loans, commercial business loans, commercial real estate mortgage loans and, to a lesser extent, one-to-four family loans (focusing on mixed-use properties, which are properties that contain both residential dwelling units and commercial units). It also operates an internet branch, under the brands of iGObanking.com and BankPurely. The company operates as a single unit, a community bank.